Azeliragon

Phase 3Small molecule

CCantex Pharmaceuticals

Azeliragon is one of 149 small molecule programs targeting High Grade Gliomas. It is currently in Phase 3.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

High Grade GliomasNot yet recruiting

HER2 PositiveNot yet recruiting

GlioblastomaActive, not recruiting

Pancreatic CancerRecruiting

PneumoniaActive, not recruiting

Stereotactic RadiationRecruiting

High Grade GliomasPhase 2

Not yet recruiting

HER2 PositivePreclinical

Not yet recruiting

GlioblastomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Recruiting

PneumoniaPhase 3

Active, not recruiting

Stereotactic RadiationPhase 2

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Azeliragon

CCantex Pharmaceuticals

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Stereotactic Radiation

NCT05789589

Q3 2029

Phase 2Not yet recruiting

High Grade Gliomas

NCT07694089

Q4 2029

PreclinicalNot yet recruiting

HER2 Positive

NCT07785856

Q3 2030

Phase 1Recruiting

Glioblastoma

NCT06831526

Clinical

Trials by Indication[1]

Glioblastoma4 trials

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

Withdrawn·—·Phase 1·NCT05773664

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Recruiting·WWashington University School of Medicine·Phase 1·NCT06831526·12 enrolled

Azeliragon in MGMT Unmethylated Glioblastoma

Active, not recruiting·CCantex Pharmaceuticals·Phase 2·NCT05986851·30 enrolled

Show 1 more trial

A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined With Conventional Concurrent Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Completed·CCantex Pharmaceuticals·Preclinical·NCT05635734·33 enrolled

Alzheimer's Disease2 trials

2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

Terminated·VvTv Therapeutics·Phase 3·NCT02916056·297 enrolled

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

Terminated·VvTv Therapeutics·Phase 3·NCT02080364·880 enrolled

Stereotactic Radiation1 trial

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Recruiting·BBaptist Health South Florida·Phase 1/2·NCT05789589·46 enrolled

Pneumonia1 trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Active, not recruiting·TThe University of Texas Medical Branch, Galveston·Phase 2/3·NCT05815485·144 enrolled

Impaired glucose tolerance1 trial

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Terminated·VvTv Therapeutics·Phase 2·NCT03980730·43 enrolled

4 more indications

Pancreatic Cancer1 trial

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Recruiting·CCantex Pharmaceuticals·Phase 1/2·NCT05766748·30 enrolled

HER2 Positive1 trial

A Phase Ib/II Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer

Not yet recruiting·TThe Methodist Hospital Research Institute·Preclinical·NCT07785856·27 enrolled

High Grade Gliomas1 trial

A Randomized Trial of Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

Not yet recruiting·AAkshitkumar MIstry·Phase 2·NCT07694089·80 enrolled

Unspecified1 trial

Concurrent Azeliragon With Craniospinal Irradiation

Recruiting·NNYU Langone Health·Phase 1·NCT06724926·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Azeliragon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azeliragon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azeliragon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cantex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCantex Pharmaceuticals

Azeliragon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2029

Q4 2029

Q3 2030

Trials by Indication[1]

Glioblastoma4 trials

Alzheimer's Disease2 trials

Stereotactic Radiation1 trial

Pneumonia1 trial

Impaired glucose tolerance1 trial

Pancreatic Cancer1 trial

HER2 Positive1 trial

High Grade Gliomas1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News